|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
|
KR101499783B1
(ko)
|
2006-04-04 |
2015-03-09 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
키나제 길항물질
|
|
WO2007125321A2
(en)
|
2006-04-25 |
2007-11-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
|
US8227603B2
(en)
*
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
|
EP2666777A1
(en)
|
2006-08-02 |
2013-11-27 |
Cytokinetics, Inc. |
Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods
|
|
US8299248B2
(en)
*
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
|
AR064415A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Cancer Rec Tech Ltd |
Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
|
|
EP2139478A4
(en)
*
|
2007-03-30 |
2010-05-05 |
Cytokinetics Inc |
CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
|
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
|
US20110160232A1
(en)
|
2007-10-04 |
2011-06-30 |
Pingda Ren |
Certain chemical entities and therapeutic uses thereof
|
|
AU2008309383B2
(en)
|
2007-10-11 |
2012-04-19 |
Astrazeneca Ab |
Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
|
|
AU2009204483B2
(en)
|
2008-01-04 |
2014-03-13 |
Intellikine, Llc |
Certain chemical entities, compositions and methods
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン， エルエルシー |
キナーゼ阻害剤および使用方法
|
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
|
US8193202B2
(en)
|
2008-04-21 |
2012-06-05 |
Lexicon Pharmaceuticals, Inc. |
LIMK2 inhibitors, compositions comprising them, and methods of their use
|
|
AR071717A1
(es)
|
2008-05-13 |
2010-07-07 |
Array Biopharma Inc |
Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
MX2011000216A
(es)
|
2008-07-08 |
2011-03-29 |
Intellikine Inc |
Inhibidores de cinasa y metodos para su uso.
|
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
|
WO2010045542A2
(en)
|
2008-10-16 |
2010-04-22 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
|
AR074072A1
(es)
|
2008-11-11 |
2010-12-22 |
Lilly Co Eli |
Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
|
|
WO2010129816A2
(en)
|
2009-05-07 |
2010-11-11 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP2789615B1
(en)
|
2009-08-11 |
2017-05-03 |
Bristol-Myers Squibb Company |
Azaindazoles as Btk kinase modulators and use thereof
|
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
|
JP5951600B2
(ja)
|
2010-05-21 |
2016-07-13 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
キナーゼ調節のための、化合物、組成物および方法
|
|
US8901133B2
(en)
|
2010-11-10 |
2014-12-02 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
JP5927201B2
(ja)
|
2010-12-16 |
2016-06-01 |
カルチャン リミテッド |
Ａｓｋ１阻害ピロロピリミジン誘導体
|
|
KR20180080358A
(ko)
|
2011-01-10 |
2018-07-11 |
인피니티 파마슈티칼스, 인코포레이티드 |
이소퀴놀린온 및 이의 고체 형태의 제조 방법
|
|
JP6130305B2
(ja)
|
2011-02-23 |
2017-05-17 |
インテリカイン， エルエルシー |
キナーゼ阻害剤の組み合わせおよびそれらの使用
|
|
BR112013025410A2
(pt)
|
2011-04-01 |
2016-12-20 |
Astrazeneca Ab |
tratamento terapêutico
|
|
WO2013010015A2
(en)
|
2011-07-13 |
2013-01-17 |
Cytokinetics, Inc. |
Combination als therapy
|
|
EP2734530A1
(en)
|
2011-07-19 |
2014-05-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
CN103998442B
(zh)
|
2011-08-29 |
2016-09-14 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
|
US8809372B2
(en)
|
2011-09-30 |
2014-08-19 |
Asana Biosciences, Llc |
Pyridine derivatives
|
|
US9199975B2
(en)
|
2011-09-30 |
2015-12-01 |
Asana Biosciences, Llc |
Biaryl imidazole derivatives for regulating CYP17
|
|
WO2013062945A1
(en)
*
|
2011-10-24 |
2013-05-02 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
CA2856646C
(en)
|
2011-11-30 |
2020-01-14 |
Astrazeneca Ab |
Combination treatment of cancer
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
WO2014052669A1
(en)
|
2012-09-26 |
2014-04-03 |
The Regents Of The University Of California |
Modulation of ire1
|
|
IL291945B2
(en)
|
2012-11-01 |
2025-11-01 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
MX389256B
(es)
|
2013-10-04 |
2025-03-20 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
|
EP4066834A1
(en)
|
2014-03-19 |
2022-10-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN108349985A
(zh)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
GB201918815D0
(en)
*
|
2019-12-19 |
2020-02-05 |
Imperial College Innovations Ltd |
Treatment of cancer
|